Assessment of immune responses of the flagellin (FliC) fused to FimH adhesin of Uropathogenic Escherichia coli

Karam, Mohammad Reza Asadi; Oloomi, Mana; Mahdavi, Mehdi; Habibi, Mehri; Bouzari, Saeid

doi:10.1016/j.molimm.2012.11.002

Cited by 32 publications

(18 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The results indicated that the increased the IFN-c level in comparison with the vaccine alone (Asadi Karam et al, 2013). However, in the study on MSP1 19 , it was shown that immunization with the flagellin-conjugated form of MSP1 19 was more effective than with a mixture in the induction of a Th1 pattern (Bargieri et al, 2010).These results confirm our findings in the induction of a Th1 pattern using P. aeruginosa flagellin as an adjuvant.…”

Section: Discussionsupporting

confidence: 83%

“…They also found that flagellin may be an efficacious adjuvant for use in humans. However, many studies have shown that FliC as an adjuvant can increase specific antibodies in combination with various vaccines (Eom et al, 2013;Karam et al, 2013;Lee et al, 2006), although we did not achieve this effect. In fact, our results with respect to antibody responses showed a weak effect of FliC on the total antibodies and only an increase in the IgM isotype was observed.…”

Section: Discussioncontrasting

confidence: 82%

“…Lymphocyte proliferation is a criterion of the cellular immune response (Mahdavi et al, 2011) and our findings suggest that FliC could stimulate a cellular immune response. Our previous study on the FimH antigen of uropathogenic E. coli showed that FliC as an adjuvant increased the lymphocyte proliferation response against the FimH antigen (Asadi Karam et al, 2013).…”

Section: Discussionmentioning

confidence: 99%

“…Because of its high immunogenicity and protective effects, bacterial flagellin can be used as a novel candidate for vaccine design (Faezi et al, 2014). Several studies have shown the adjuvant activity of the FliC molecule in combination with various vaccine models (Asadi Karam et al, 2013;Girard et al, 2014;Lee et al, 2006;Mizel and Bates, 2010;Yin et al, 2013). However, key questions remain such as how the FliC molecule should be used in order to maximize its adjuvant activity.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Pseudomonas aeruginosa flagellin as an adjuvant: superiority of a conjugated form of flagellin versus a mixture with a human immunodeficiency virus type 1 vaccine candidate in the induction of immune responses

Delavari

Sohrabi

Ardestani

et al. 2015

Journal of Medical Microbiology

Self Cite

View full text Add to dashboard Cite

In the present study, the adjuvant activity of flagellin was compared, in the conjugated and mixed forms, against a peptide vaccine from human immunodeficiency virus type 1 (HIV-1) p24-Nef vaccine candidate. Mice were immunized with the HIV-1 p24-Nef peptide with flagellin in both conjugated and mixed forms. Lymphocyte proliferation, CTL activity, and IL-4 and IFN-c cytokines were evaluated by bromodeoxyuridine, carboxyfluorescein succinimidyl ester and ELISA methods, respectively. At the same time, the frequency of IFN-c-producing T-lymphocytes, as well as total and isotype-specific antibodies, were assessed by ELISPOT and indirect ELISA, respectively. Our experimental results showed that the immunized mice with the HIV-1 p24-Nef conjugated or mixed forms of flagellin led to increases in the proliferative responses and Th1 cytokine pattern. The conjugated form of vaccine led to increased CTL activity and a Th1 cytokine pattern of immune responses, as well as an IgM isotype of humoral responses in comparison with the mixed form. The flagellin-conjugated vaccine seems to be more potent in increasing vaccine immunogenicity.

show abstract

Section: Discussionsupporting

confidence: 83%

Section: Discussioncontrasting

confidence: 82%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Pseudomonas aeruginosa flagellin as an adjuvant: superiority of a conjugated form of flagellin versus a mixture with a human immunodeficiency virus type 1 vaccine candidate in the induction of immune responses

Delavari

Sohrabi

Ardestani

et al. 2015

Journal of Medical Microbiology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Two phase II trials are planned. One will recruit 90 women who have a history of recurrent UTI and the second will enlist 300 women who have no history of UTI or have had only sporadic cases (Asadi Karam et al, 2013;Karam et al, 2013).…”

Section: Genetic Variants Affecting Adaptive Immunitymentioning

confidence: 99%

Urinary Tract Infections and the Mucosal Immune System

Godaly¹,

Bergsten²,

Fischer³

et al. 2015

Mucosal Immunology

View full text Add to dashboard Cite

Characterization of structural and immunological properties of a fusion protein between flagellin from Salmonella and lumazine synthase from Brucella

et al. 2017

View full text Add to dashboard Cite

Aiming to combine the flexibility of Brucella lumazine synthase (BLS) to adapt different protein domains in a decameric structure and the capacity of BLS and flagellin to enhance the immunogenicity of peptides that are linked to their structure, we generated a chimeric protein (BLS-FliC131) by fusing flagellin from Salmonella in the N-termini of BLS. The obtained protein was recognized by anti-flagellin and anti-BLS antibodies, keeping the oligomerization capacity of BLS, without affecting the folding of the monomeric protein components determined by circular dichroism. Furthermore, the thermal stability of each fusion partner is conserved, indicating that the interactions that participate in its folding are not affected by the genetic fusion. Besides, either in vitro or in vivo using TLR5-deficient animals we could determine that BLS-FliC131 retains the capacity of triggering TLR5. The humoral response against BLS elicited by BLS-FliC131 was stronger than the one elicited by equimolar amounts of BLS + FliC. Since BLS scaffold allows the generation of hetero-decameric structures, we expect that flagellin oligomerization on this protein scaffold will generate a new vaccine platform with enhanced capacity to activate immune responses.

show abstract

Assessment of immune responses of the flagellin (FliC) fused to FimH adhesin of Uropathogenic Escherichia coli

Cited by 32 publications

References 37 publications

Pseudomonas aeruginosa flagellin as an adjuvant: superiority of a conjugated form of flagellin versus a mixture with a human immunodeficiency virus type 1 vaccine candidate in the induction of immune responses

Pseudomonas aeruginosa flagellin as an adjuvant: superiority of a conjugated form of flagellin versus a mixture with a human immunodeficiency virus type 1 vaccine candidate in the induction of immune responses

Urinary Tract Infections and the Mucosal Immune System

Characterization of structural and immunological properties of a fusion protein between flagellin from Salmonella and lumazine synthase from Brucella

Contact Info

Product

Resources

About